<DOC>
	<DOCNO>NCT01860170</DOCNO>
	<brief_summary>The purpose study determine Bortezomib , know commercially Velcade safe tolerate different dose level ( amount ) high dose Cyclophosphamide use graft versus host disease prevention reduced-intensity allogeneic hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Post-Transplant Bortezomib High Dose Cyclophosphamide Graft-Versus-Host Disease ( GVHD ) Prophylaxis</brief_title>
	<detailed_description>It hypothesize administration early short course cyclophosphamide bortezomib allogeneic hematopoietic stem cell transplantationin set match related unrelated donor transplantation use standard reduced-intensity conditioning regimen feasible . The study phase I study . The primary objective study determine feasibility safety increase dos bortezomib administer post-transplant conjunction fix high dose cyclophosphamide , also administer post-transplant set reduced-intensity allogeneic hematopoietic stem cell transplant , GVHD prophylaxis strategy . Eligible patient receive condition regimen base combination fludarabine busulfan without rATG .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria 1 . 8 8 match relate unrelated donor 2 . Age &gt; 18 year 3 . Good performance status Karnofsky score &gt; /= 70 % 4 . No evidence progressive bacterial , viral fungal infection despite adequate treatment 5 . Creatinine clearance &gt; 40 mL/min/1.72m2 6 . Total bilirubin &lt; 1.5 ALT AST &lt; 2 time upper limit normal 7 . Cardiac ejection fraction &gt; 40 % 8 . DLCO &gt; 50 % 9 . Negative pregnancy test 10 . Negative HIV serology 11 . Able provide inform consent 12 . Female subject either postmenopausal least 1 year screen visit , surgically sterilize childbearing potential , agree practice 2 effective method contraception time sign informed consent form 30 day last dose bortezomib , agree completely abstain heterosexual intercourse . 13 . Male subject , even surgically sterilize ( ie , status postvasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . 1 . Age &lt; 18 year 2 . Poor performance status ( &lt; 70 % ) 3 . Active infection 4 . Abnormal creatinine clearance &lt; 40ml/min 5 . Elevated bilirubin &gt; 1.5 ALT AST .2 time upper limit normal 6 . Poor ejection fraction &lt; 40 % 7 . DLCO &lt; 50 % 8 . Pregnant female . 9 . HIV positive 10 . Inability provide inform consent 11 . Patient &gt; /= Grade 2 peripheral neuropathy 12 . Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . 13 . Patient hypersensitivity bortezomib , boron , mannitol . 14 . Serious medical psychiatric illness likely interfere participation clinical study . 15 . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . 16 . Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Blood Marrow Transplant ( BMT )</keyword>
	<keyword>MRD</keyword>
	<keyword>MUD</keyword>
	<keyword>GVHD</keyword>
</DOC>